arrow
R

Rakesh Aggarwal

Jawaharlal Institute of Postgraduate Medical Education and Research
H指数:71
被引数:8.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nor-ursodeoxycholic acid for metabolic dysfunction-associated steatotic liver disease: is there enough evidence for clinical use? A critique of a phase III trial and regulatory endorsement of the drug

诺ursoxycholic酸用于代谢功能障碍相关脂肪性肝病:是否有足够的证据支持临床使用?——一项对III期试验和药物监管批准的批判性分析

2026-03-090
PRE
Erratum to “Report from the World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) meeting, virtual gathering, 1–5 September 2025” [Vaccine 68 (2025) 127903]

《世界卫生组织免疫接种相关实施研究咨询委员会(IVIR-AC)会议报告》(虚拟会议,2025年9月1日至5日)勘误 [Vaccine 68 (2025) 127903]

Vaccine
IF3.5
2025-11-180
OAAI
Report from the World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) meeting, virtual gathering, 1–5 September 2025

世界卫生组织免疫接种及相关实施研究咨询委员会(IVIR-AC)会议报告,线上会议,2025年9月1日至5日

Vaccine
IF3.5
2025-11-010
OAAI
CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials

CONSORT 2025声明:随机试验报告更新指南

2025-06-102
PRE
SPIRIT 2025 statement: updated guideline for protocols of randomized trials

SPIRIT 2025声明:随机试验方案更新的指南[epub ahead of print]

2025-04-290
PRE
A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up

一类口服先天免疫激活剂BXCL701联合帕博利珠单抗治疗转移性去势抵抗性前列腺癌(mCRPC)患者的II期研究:长期随访

2024-09-010
PRE
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update
2024-04-0118
PRE